Tag:
Albuferon
Latest Headlines
Latest Headlines
HGS relies on lupus data to calm riled investors
Can Human Genome Sciences pull out of its nosedive? That's essentially the question that the Washington Post poses as it examines a high-profile biotech company that has stumbled at a critical point
HGS unveils positive Hep C data
Human Genome Sciences' experimental hepatitis C drug Albuferon met its primary endpoint of non-inferiority to Pegasys in a Phase III trial. The drug was effective in treating patients with genotype 1
HGS shares soar on late-stage success
Shares of Human Genome Sciences soared 30 percent earlier today after researchers reported that Albuferon hit its primary goal in a late-stage trial. Albuferon delivered data demonstrating that it is
HGS stock dives on drug safety concerns
Human Genome Sciences watched its stock take a dive this morning after an independent data monitoring committee noted lung-related side effects in patients receiving 1200-microgram injections of the
HGS pockets $40M for Albuferon, preps Phase III
Human Genome Sciences can bank a $40 million pay check from Novartis, its milestone for a successful Phase IIa trial of
